High Speed and High Resolution SEC Analysis of Antibodies Using TSKgel SuperSW mAB Columns
Tosoh Bioscience
Antibody therapeutics are enjoying high growth rates in the biopharmaceutical market, with the major areas of therapeutic application being cancer and immune/inflammation-related disorders including arthritis and multiple sclerosis. In 2010, four of the top ten best-selling global drug brands were monoclonal antibodies (mAbs). The characterization of these complex biomolecules is a major challenge in process monitoring and quality control (QC). The main product characteristics to be monitored are aggregate and fragment content, glycosylation pattern and charged isoforms. The standard method used in biopharmaceutical QC for mAb aggregate and fragment analysis is size exclusion chromatography (SEC). A new series of silica-based HPLC columns can be applied to either increase speed or improve resolution of the separation of antibody fragments, monomers and dimers.
Experimental
IgG was digested with papain over 24 h. The fragmentation process was monitored by analysing 10 or 5 μl aliquots of the sample.
Mobile phase: 200 mmol/L phosphate buffer + 0.05% NaN3, pH 6.7
Flow rate: a & b: 1.0 mL/min; c: 0.35 mL/min
Injection vol.: a & b: 10 μl; c: 5 μL
Temperature: 25 °C
Detection: UV @ 280 nm
Samples: 10 g/L IgG digested with papain for 0–24 h
Columns: a: TSKgel G3000SWXL, 7.8 mm i.d. × 30 cm
b: TSKgel SuperSW mAb HR, 7.8 mm i.d. × 30 cm
c: TSKgel SuperSW mAb HTP, 4.6 mm i.d. × 15 cm
Results
Figure 1a shows the separation of a papain digested immunoglobulin G sample on a TSKgel G3000SWXL column, which is applied as the standard SEC column in routine analysis of aggregates in many QC and R&D labs. Figure 1b demonstrates that the resolution of the separation can be improved by using the new TSKgel SuperSW mAb HR (High Resolution) with 4 micron silica particles. This column provides higher resolution than the conventional column at the same analysis time. Using the TSKgel SuperSW mAb HTP (High Throughput), a short semi-micro column packed with the same 4 micron particles as SuperSW mAb HR, dimer, monomer and fragments were separated at the same resolving power as on the conventional column but in half the analysis time (Figure 1c).
Figure 1: Separation of antibody fragments, monomers and dimers by size exclusion chromatography (SEC). a: TSKgel G3000SWXL, 7.8 mm i.d. Ã 30 cm; b: TSKgel SuperSW mAb HR, 7.8 mm i.d. Ã 30 cm; c: TSKgel SuperSW mAb HTP, 4.6 mm i.d. Ã 15 cm.
Summary
SEC is a common method for the separation of antibody monomer from dimer, aggregates or degradation products on the basis of molecular size. Two novel SEC columns designed for antibody separation exhibit reduced analysis time while achieving baseline separation or enhanced resolution between monomer and dimer.
Tosoh Bioscience GmbH
Zettachring 6, 70567 Stuttgart, Germany
tel. +49 (0)711 13257 0 fax +49 (0)711 13257 89
E-mail: info.tbg@tosoh.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
